Cutaneous lupus erythematosus
Identifieur interne : 001409 ( Main/Exploration ); précédent : 001408; suivant : 001410Cutaneous lupus erythematosus
Auteurs : Christopher B. Hansen [États-Unis] ; Kevin W. Dahle [États-Unis]Source :
- Dermatologic Therapy [ 1396-0296 ] ; 2012-03.
English descriptors
- Teeft :
- Acad, Acad dermatol, Acitretin, Acta derm venereol, Actinic keratoses, Antimalarial, Arch dermatol, Arthritis rheum, Azathioprine, Case report, Case reports, Chloroquine, Clin, Clinical presentation, Clobetasol propionate, Common side effects, Complete resolution, Cutaneous, Cutaneous lesions, Cutaneous lupus erythematosus, Cutaneous lupus erythematosus disease area, Cyclophosphamide, Cyclosporine, Dahle, Dapsone, Dermatol, Dermatologic, Dermatologic conditions, Dermatology, Discoid, Discoid lesions, Discoid lupus erythematosus, Dos, Efalizumab, Erythematosus, Etanercept, Good response, Hansen dahle, Hydroxychloroquine, Hypertrophic, Imiquimod, Immunoglobulin, Intravenous, Intravenous immunoglobulin, Isotretinoin, Ivig, Kuhn, Lesion, Lupus, Lupus erythematosus, Lupus erythematosus profundus, Lupus skin disease, Methotrexate, Mofetil, Mycophenolate, Mycophenolate mofetil, Mycophenolate sodium, Peripheral neuropathy, Pimecrolimus, Randomized, Rash, Recalcitrant, Refractory, Refractory subacute cutaneous lupus erythematosus, Remission, Resistant scle, Rheumatoid arthritis, Rituximab, Ruzicka, Scarring, Scle, Severity index, Side effects, Skin lesions, Steroid, Subacute, Subacute cutaneous lupus erythematosus, Subacute lupus erythematosus, Successful treatment, Sunscreen, Systemic, Systemic lupus erythematosus, Tacrolimus, Tacrolimus ointment, Thalidomide, Topical retinoids, Topical steroids, Urticarial vasculitis, Various forms.
Abstract
Cutaneous lupus erythematosus is a heterogeneous autoimmune condition that can significantly impact quality of life. Treatment is focused on reducing clinical inflammation and preventing scarring. The choice of treatment should be guided based on the severity of disease. Mild or localized disease can be treated with sun protection and topical agents. Antimalarials are the initial treatment of choice if systemic therapy is required. Patients with severe or unresponsive disease can also be treated with a number of other immunomodulating or immunosuppressive agents. Clinicians should be aware of their potential adverse effects and appropriate dosing.
Url:
DOI: 10.1111/j.1529-8019.2012.01508.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000067
- to stream Istex, to step Curation: 000067
- to stream Istex, to step Checkpoint: 000418
- to stream Main, to step Merge: 001410
- to stream Main, to step Curation: 001409
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cutaneous lupus erythematosus</title>
<author><name sortKey="Hansen, Christopher B" sort="Hansen, Christopher B" uniqKey="Hansen C" first="Christopher B." last="Hansen">Christopher B. Hansen</name>
</author>
<author><name sortKey="Dahle, Kevin W" sort="Dahle, Kevin W" uniqKey="Dahle K" first="Kevin W." last="Dahle">Kevin W. Dahle</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:4F9D4A36CF81F7690D1B9B3D136F8AAD701FB65E</idno>
<date when="2012" year="2012">2012</date>
<idno type="doi">10.1111/j.1529-8019.2012.01508.x</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-NT2KV4X4-N/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000067</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000067</idno>
<idno type="wicri:Area/Istex/Curation">000067</idno>
<idno type="wicri:Area/Istex/Checkpoint">000418</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000418</idno>
<idno type="wicri:doubleKey">1396-0296:2012:Hansen C:cutaneous:lupus:erythematosus</idno>
<idno type="wicri:Area/Main/Merge">001410</idno>
<idno type="wicri:Area/Main/Curation">001409</idno>
<idno type="wicri:Area/Main/Exploration">001409</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Cutaneous lupus erythematosus</title>
<author><name sortKey="Hansen, Christopher B" sort="Hansen, Christopher B" uniqKey="Hansen C" first="Christopher B." last="Hansen">Christopher B. Hansen</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Dermatology, University of Utah, Utah, Salt Lake City</wicri:regionArea>
<wicri:noRegion>Salt Lake City</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Dahle, Kevin W" sort="Dahle, Kevin W" uniqKey="Dahle K" first="Kevin W." last="Dahle">Kevin W. Dahle</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Dermatology, University of Utah, Utah, Salt Lake City</wicri:regionArea>
<wicri:noRegion>Salt Lake City</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Dermatologic Therapy</title>
<title level="j" type="sub">Management of collagen vascular disease and related disorders</title>
<title level="j" type="alt">DERMATOLOGIC THERAPY</title>
<idno type="ISSN">1396-0296</idno>
<idno type="eISSN">1529-8019</idno>
<imprint><biblScope unit="vol">25</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="99">99</biblScope>
<biblScope unit="page" to="111">111</biblScope>
<biblScope unit="page-count">13</biblScope>
<date type="published" when="2012-03">2012-03</date>
</imprint>
<idno type="ISSN">1396-0296</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1396-0296</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acad</term>
<term>Acad dermatol</term>
<term>Acitretin</term>
<term>Acta derm venereol</term>
<term>Actinic keratoses</term>
<term>Antimalarial</term>
<term>Arch dermatol</term>
<term>Arthritis rheum</term>
<term>Azathioprine</term>
<term>Case report</term>
<term>Case reports</term>
<term>Chloroquine</term>
<term>Clin</term>
<term>Clinical presentation</term>
<term>Clobetasol propionate</term>
<term>Common side effects</term>
<term>Complete resolution</term>
<term>Cutaneous</term>
<term>Cutaneous lesions</term>
<term>Cutaneous lupus erythematosus</term>
<term>Cutaneous lupus erythematosus disease area</term>
<term>Cyclophosphamide</term>
<term>Cyclosporine</term>
<term>Dahle</term>
<term>Dapsone</term>
<term>Dermatol</term>
<term>Dermatologic</term>
<term>Dermatologic conditions</term>
<term>Dermatology</term>
<term>Discoid</term>
<term>Discoid lesions</term>
<term>Discoid lupus erythematosus</term>
<term>Dos</term>
<term>Efalizumab</term>
<term>Erythematosus</term>
<term>Etanercept</term>
<term>Good response</term>
<term>Hansen dahle</term>
<term>Hydroxychloroquine</term>
<term>Hypertrophic</term>
<term>Imiquimod</term>
<term>Immunoglobulin</term>
<term>Intravenous</term>
<term>Intravenous immunoglobulin</term>
<term>Isotretinoin</term>
<term>Ivig</term>
<term>Kuhn</term>
<term>Lesion</term>
<term>Lupus</term>
<term>Lupus erythematosus</term>
<term>Lupus erythematosus profundus</term>
<term>Lupus skin disease</term>
<term>Methotrexate</term>
<term>Mofetil</term>
<term>Mycophenolate</term>
<term>Mycophenolate mofetil</term>
<term>Mycophenolate sodium</term>
<term>Peripheral neuropathy</term>
<term>Pimecrolimus</term>
<term>Randomized</term>
<term>Rash</term>
<term>Recalcitrant</term>
<term>Refractory</term>
<term>Refractory subacute cutaneous lupus erythematosus</term>
<term>Remission</term>
<term>Resistant scle</term>
<term>Rheumatoid arthritis</term>
<term>Rituximab</term>
<term>Ruzicka</term>
<term>Scarring</term>
<term>Scle</term>
<term>Severity index</term>
<term>Side effects</term>
<term>Skin lesions</term>
<term>Steroid</term>
<term>Subacute</term>
<term>Subacute cutaneous lupus erythematosus</term>
<term>Subacute lupus erythematosus</term>
<term>Successful treatment</term>
<term>Sunscreen</term>
<term>Systemic</term>
<term>Systemic lupus erythematosus</term>
<term>Tacrolimus</term>
<term>Tacrolimus ointment</term>
<term>Thalidomide</term>
<term>Topical retinoids</term>
<term>Topical steroids</term>
<term>Urticarial vasculitis</term>
<term>Various forms</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">Cutaneous lupus erythematosus is a heterogeneous autoimmune condition that can significantly impact quality of life. Treatment is focused on reducing clinical inflammation and preventing scarring. The choice of treatment should be guided based on the severity of disease. Mild or localized disease can be treated with sun protection and topical agents. Antimalarials are the initial treatment of choice if systemic therapy is required. Patients with severe or unresponsive disease can also be treated with a number of other immunomodulating or immunosuppressive agents. Clinicians should be aware of their potential adverse effects and appropriate dosing.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Hansen, Christopher B" sort="Hansen, Christopher B" uniqKey="Hansen C" first="Christopher B." last="Hansen">Christopher B. Hansen</name>
</noRegion>
<name sortKey="Dahle, Kevin W" sort="Dahle, Kevin W" uniqKey="Dahle K" first="Kevin W." last="Dahle">Kevin W. Dahle</name>
<name sortKey="Hansen, Christopher B" sort="Hansen, Christopher B" uniqKey="Hansen C" first="Christopher B." last="Hansen">Christopher B. Hansen</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001409 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001409 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:4F9D4A36CF81F7690D1B9B3D136F8AAD701FB65E |texte= Cutaneous lupus erythematosus }}
This area was generated with Dilib version V0.6.33. |